Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,057.02 5.99 (0.57%) as of 4:30 Mon 7/1


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 110.66(B)
Last Volume: 383,195 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,108 255,165 311,759 469,743
Total Sell Value $188,697,290 $247,812,013 $294,950,701 $405,465,351
Total People Sold 7 14 16 18
Total Sell Transactions 18 43 67 128
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 2430
  Page 52 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Aberman Michael S SVP Strategy Investor Relation   •       –      –    2015-02-13 4 D $402.05 $1,531,006 D/D (3,808) 22,292     -
   Aberman Michael S SVP Strategy Investor Relation   •       –      –    2015-02-13 4 OE $24.00 $180,000 D/D 7,500 26,100     -
   Vagelos P Roy Chairman of the Board   •       •      –    2015-01-06 4 GD $0.00 $0 I/I 511 155,266     -
   Schleifer Leonard S President & CEO   •       •      –    2015-01-02 4 AS $408.64 $615,867 I/I (1,500) 0     -
   Schleifer Leonard S President & CEO   •       •      –    2015-01-02 4 A $0.00 $0 I/I 1,500 1,500     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2015-01-02 4 AS $410.99 $4,481,214 D/D (10,822) 10,711     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2014-12-31 4 D $412.78 $5,852,395 D/D (14,178) 21,533     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2014-12-31 4 OE $52.03 $1,300,750 D/D 25,000 35,711     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-12-24 4 B $392.72 $11,964,501 I/I 30,002 22,859,144 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-12-23 4 B $384.43 $67,251,142 I/I 171,457 22,829,142 1.5     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2014-12-19 4 OE $30.63 $99,976 D/D 3,264 10,711     -
   Van Plew Daniel P SVP & General Mgr Industrial O   •       –      –    2014-12-18 4 OE $30.63 $99,976 D/D 3,264 18,705     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2014-12-17 4 OE $30.63 $85,764 D/D 2,800 7,481     -
   Goldberg Murray A SVP Administration & Asst Secr   •       –      –    2014-12-16 4 OE $30.63 $99,976 D/D 3,264 64,436     -
   Stahl Neil SVP Research and Development S   •       –      –    2014-12-16 4 OE $30.63 $99,976 D/D 3,264 6,541     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2014-12-16 4 GA $0.00 $0 I/I 3,264 569,588     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2014-12-16 4 GD $0.00 $0 D/D 3,264 500,000     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2014-12-16 4 OE $30.63 $99,976 D/D 3,264 503,264     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2014-12-16 4 AS $410.00 $2,795,380 D/D (6,818) 4,681     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2014-12-16 4 OE $30.63 $334,560 D/D 6,818 10,556     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2014-12-15 4 AS $410.16 $685,144 D/D (1,668) 4,681     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2014-12-15 4 OE $30.63 $51,091 D/D 1,668 6,049     -
   Poon Christine A Director   –       •      –    2014-11-25 4 B $410.00 $164,000 D/D 400 655 2.39     -
   Brown Michael S Director   –       •      –    2014-11-24 4 GD $0.00 $0 I/I 2,000 18,349     -
   Gilman Alfred G Director   –       •      –    2014-11-24 4 S $405.65 $16,337,585 D/D (40,000) 0     -
  2430 Records found
  Previous  50  51  52  53  54  55  56  57  58  59  Next   
  Page 52 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us